Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of medicine for treating cerebral ischemic dementia and preparation method thereof

A technology for cerebral ischemia and ischemic brain, applied in drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve the lack of objective laboratory evidence for diagnosis and efficacy judgment, and the lack of large-scale placebo control Clinical research, the selection of positive control drugs is not representative, etc., to achieve the effect of reducing the rate of brain lipid peroxidation, improving bioavailability, and repairing dynamic balance disorders

Active Publication Date: 2015-12-16
郭涛 +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The public literature search of Huperzine A Tablets in the treatment of dementia and the analysis of the results revealed the following problems in the current research: 1. The course of treatment was too short and the number of samples was too small; 2. The selection of positive control drugs was not representative ; 3. Lack of large-scale placebo-controlled clinical research; 4. Lack of objective laboratory evidence for diagnosis and efficacy judgment
[0009] So far, we have not found precedents and reports of using a drug made by combining huperzine A and ginkgolide B to treat ischemic dementia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of medicine for treating cerebral ischemic dementia and preparation method thereof
  • A kind of medicine for treating cerebral ischemic dementia and preparation method thereof
  • A kind of medicine for treating cerebral ischemic dementia and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1: Preparation of Huperzine A and Ginkgolide B Solid Lipid Nanoparticles

[0058] The ingredients are effective doses of huperzine A 0.1 mg, ginkgolide B 10 mg, glyceryl monostearate 2.0 g, sodium taurocholate 0.2 g, poloxamer 1880.6 g, and the rest is liquid phase water, 100 ml in total.

[0059] Preparation:

[0060] a. In the preparation tank, stir the prescribed amount of emulsifier at 75°C for 30 minutes, and disperse evenly to form a water phase;

[0061] b. In the preparation tank, melt the prescribed amount of solid lipid phase at 65°C, then add the prescribed amount of huperzine A and ginkgolide B, and stir evenly to form the lipid phase;

[0062] c. Quickly add the water phase to the lipid phase at one time, stir at high speed (6000rpm) for 10 minutes, and make colostrum;

[0063] d. Pass through a homogenizer, adjust the homogenization pressure to 100MPa, repeat the homogenization of the solution 5 times to obtain a uniform emulsion, pass through...

Embodiment 2

[0064] Embodiment 2: Preparation of Huperzine A and Ginkgolide B Solid Lipid Nanoparticles

[0065] The ingredients are effective doses of huperzine A 0.15 mg, ginkgolide B 5 mg, glycerol monostearate 1.0 g, lecithin 0.5 g, poloxamer F68 1.6 g, and the rest is liquid phase water, 100 ml in total.

[0066] Preparation:

[0067] a. In the preparation tank, stir and disperse the prescribed amount of emulsifier at 80°C to make a water phase;

[0068] b. In the preparation tank, melt the prescribed amount of solid lipid phase at 70°C, then add the prescribed amount of huperzine A and ginkgolide B, and stir evenly to form a lipid phase;

[0069] c. Quickly add the water phase to the lipid phase at one time, stir at high speed (6000rpm) for 10 minutes, and make colostrum;

[0070] d. Pass through a homogenizer (or microfluidizer), adjust the homogenization pressure to 100MPa, repeat the homogenization of the solution 4 times to obtain a uniform emulsion, pass through a microporous ...

Embodiment 3

[0071] Embodiment 3: Preparation of Huperzine A and Ginkgolide B Solid Lipid Nanoparticles

[0072] The ingredients are effective doses of huperzine A 0.2mg and ginkgolide B 15mg, glyceryl monostearate 1.0g, sodium taurocholate 0.5g, poloxamer F68 1.6g, and the rest is liquid phase water, 100ml in total .

[0073] Preparation:

[0074] a. In the preparation tank, stir and disperse the prescribed amount of emulsifier at 90°C to make a water phase;

[0075] b. In the preparation tank, melt the prescribed amount of solid lipid phase at 80°C, then add the prescribed amount of huperzine A and ginkgolide B, and stir evenly to form the lipid phase;

[0076] c. Quickly add the water phase to the lipid phase at one time, stir at high speed (6000rpm) for 10 minutes, and make colostrum;

[0077] d. Ultrasound the colostrum for 5 minutes with a probe at a power of 400W, keep at 70°C to obtain a uniform emulsion, pass through a microporous membrane, and cool down to room temperature to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of biological pharmacy and particularly relates to a medicine used for treating cerebral ischemic dementia and a preparation method for the medicine. The medicine is prepared mainly from huperzine A and bilobalide B or is a solid lipid nanoparticle prepared by combining the huperzine a and the bilobalide B, wherein the mass ratio of the huperzine A to the bilobalide B is (0.05-0.5):(5-50). The invention aims to solve the problems that a huperzine A tablet medicine is very low in oral bioavailability, is not easy to pass through a blood brain barrier and is influenced in absorption; by simply using a ginkgo biloba extract tablet and an injection, the operation is simple, but the dose required by a patient every day is very high, and numerous side effects can be brought to the patient after the ginkgo biloba extract tablet and the injection are used for a long term; and in most of traditional medicines for treating the ischemic dementia, the huperzine A and certain traditional Chinese medicines are jointly applied, thus, the components are complicated; the mechanism of action is not clear; and the repeatability is low.

Description

Technical field: [0001] The invention belongs to the field of biopharmaceuticals, in particular to a medicine for treating cerebral ischemic dementia and a preparation method thereof. Background technique: [0002] In recent years, natural disasters and emergencies have occurred frequently in our country. In these unexpected events, the disability caused by traumatic brain injury accounts for a high proportion, and the subsequent ischemic dementia has caused great pain to people. It has caused a great burden to the society and caused combat attrition to the army. After cerebral ischemia, due to brain tissue ischemia and hypoxia, acute necrosis of nerve cells in the ischemic center area occurs, while in the ischemic penumbra area, nerve cells undergo delayed death mainly apoptosis, and apoptosis It will not stop after the blood supply is restored, which is related to the development and expansion of the brain tissue damage area after ischemia. Therefore, inhibiting apoptosi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61K9/107A61P9/10A61P25/28A61K31/365
Inventor 郭涛张琦孙学惠刘丛丛
Owner 郭涛
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com